EGFR and non-small cell lung carcinoma: However, Izar et al [12] demonstrated that patients with EGFR mutations had significantly longer disease-free survival (DFS) and overall survival (OS) than patients with wild-type EGFR and that EGFR mutation status was an independent prognostic marker for DFS in completely resected stage I NSCLC.